Literature DB >> 15907591

Gelatinase-mediated migration and invasion of cancer cells.

Mikael Björklund1, Erkki Koivunen.   

Abstract

The matrix metalloproteinases(MMP)-2 and -9, also known as the gelatinases have been long recognized as major contributors to the proteolytic degradation of extracellular matrix during tumor invasion. In the recent years, a plethora of non-matrix proteins have also been identified as gelatinase substrates thus significantly broadening our understanding of these enzymes as proteolytic executors and regulators in various physiological and pathological states including embryonic growth and development, angiogenesis and tumor progression, inflammation, infective diseases, degenerative diseases of the brain and vascular diseases. Although the effect of broad-spectrum inhibitors of MMPs in the treatment of cancer has been disappointing in clinical trials, novel mechanisms of gelatinase inhibition have been now identified. Inhibition of the association of the gelatinases with cell-surface integrins appears to offer highly specific means to target these enzymes without inhibiting their catalytic activity in multiple cell types including endothelial cells, tumor cells and leukocytes. Here, we review the multiple functions of the gelatinases in cancer, and especially their role in the tumor cell migration and invasion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15907591     DOI: 10.1016/j.bbcan.2005.03.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  216 in total

1.  MMP2 expression is a prognostic marker for primary melanoma patients.

Authors:  Anand Rotte; Magdalena Martinka; Gang Li
Journal:  Cell Oncol (Dordr)       Date:  2012-06-06       Impact factor: 6.730

2.  TIMP-1 deficiency leads to lethal partial hepatic ischemia and reperfusion injury.

Authors:  Sergio Duarte; Takashi Hamada; Naohisa Kuriyama; Ronald W Busuttil; Ana J Coito
Journal:  Hepatology       Date:  2012-07-11       Impact factor: 17.425

3.  MMP9 polymorphisms and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study.

Authors:  Alicia Beeghly-Fadiel; Wei Lu; Xiao-Ou Shu; Jirong Long; Qiuyin Cai; Yongbin Xiang; Yu-Tang Gao; Wei Zheng
Journal:  Breast Cancer Res Treat       Date:  2010-08-20       Impact factor: 4.872

4.  Ocimum gratissimum retards breast cancer growth and progression and is a natural inhibitor of matrix metalloproteases.

Authors:  Pratima Nangia-Makker; Tirza Raz; Larry Tait; Malathy P V Shekhar; Hong Li; Vitaly Balan; Hemanckur Makker; Rafael Fridman; Krishnarao Maddipati; Avraham Raz
Journal:  Cancer Biol Ther       Date:  2013-02-04       Impact factor: 4.742

5.  Chloride intracellular channel 1 regulates colon cancer cell migration and invasion through ROS/ERK pathway.

Authors:  Pan Wang; Yun Zeng; Tao Liu; Chao Zhang; Pei-Wu Yu; Ying-Xue Hao; Hua-Xin Luo; Gang Liu
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

6.  miR-486-5p regulates the migration and invasion of colorectal cancer cells through targeting PIK3R1.

Authors:  Yuhao Zhang; Jun Fu; Zhijin Zhang; Huanlong Qin
Journal:  Oncol Lett       Date:  2018-03-12       Impact factor: 2.967

7.  Ras-related protein Rap2c promotes the migration and invasion of human osteosarcoma cells.

Authors:  Jinxia Wu; Wenqi Du; Xiucun Wang; Lulu Wei; Yaojie Pan; Xiaojin Wu; Jinling Zhang; Dongsheng Pei
Journal:  Oncol Lett       Date:  2018-02-07       Impact factor: 2.967

Review 8.  Profiling distinct mechanisms of tumour invasion for drug discovery: imaging adhesion, signalling and matrix turnover.

Authors:  Neil O Carragher
Journal:  Clin Exp Metastasis       Date:  2008-10-29       Impact factor: 5.150

9.  Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype.

Authors:  Baisakhi Raychaudhuri; Yulong Han; Tao Lu; Michael A Vogelbaum
Journal:  J Neurooncol       Date:  2007-05-04       Impact factor: 4.130

10.  Terminalia catappa Exerts Antimetastatic Effects on Hepatocellular Carcinoma through Transcriptional Inhibition of Matrix Metalloproteinase-9 by Modulating NF-κB and AP-1 Activity.

Authors:  Chao-Bin Yeh; Ming-Ju Hsieh; Yih-Shou Hsieh; Ming-Hsien Chien; Pen-Yuan Lin; Hui-Ling Chiou; Shun-Fa Yang
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-08       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.